Latest European Union News

Sarytogan Graphite Limited has raised $1.8 million through a placement to fund its Definitive Feasibility Study and advance key project development activities at its strategic graphite deposit in Kazakhstan.

Straker Ltd reports a solid first half of FY26 with positive EBITDA and a renewed IBM partnership, despite a 15% revenue decline amid challenging market conditions.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Sea Forest Limited launches a $20.5 million IPO on the ASX to scale production and commercialisation of SeaFeed™, a scientifically validated livestock feed additive that cuts methane emissions by up to 80% while boosting productivity.

Prescient Therapeutics has achieved a key regulatory milestone with the European Medicines Agency granting Orphan Drug Designation for its PTX-100 therapy targeting Cutaneous T-cell Lymphomas, enhancing its commercial and clinical prospects in Europe.

Osmond Resources has reported exceptional assay results from its first drill hole at the Orión EU Critical Minerals Project, confirming high-grade titanium, zircon, and rare earth mineralisation. The discovery positions the project as a significant potential supplier of critical minerals within the EU.

Zoono Group has signed a five-year exclusive contract with Multisteps Pty Limited to apply its antimicrobial technology to fresh produce packaging in Australia, aiming to reduce food waste and boost sustainability.

Krakatoa Resources reports significant progress in drilling at its Zopkhito Antimony-Gold Project in Georgia, with most holes intersecting visible antimony mineralisation. Assay results are eagerly awaited to validate historical resource estimates and support a maiden JORC-compliant Mineral Resource.

Sarytogan Graphite Limited has reported the last batch of assays from its Reserve definition drilling at the Sarytogan Deposit, confirming thick, high-grade graphite mineralisation that will underpin a resource upgrade and advance its Definitive Feasibility Study.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

Aeris Resources has completed an $80 million equity placement and launched a share purchase plan, strengthening its balance sheet and setting ambitious production targets for FY26. The company is also divesting non-core assets to focus on growth and exploration.

Neuren Pharmaceuticals reported a milestone quarter with DAYBUE net sales reaching US$101.1 million, driving a 24% jump in royalty income. The expanding patient base and community physician uptake signal strong growth ahead.